Clinical Trials
47 trialsCT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
EVEREST-2
A2 Biotherapeutics Inc.
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
ETCABIO
University Hospital, Angers
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Stella Pharma Corporation
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
ABILITY-1
Medicenna Therapeutics, Inc.
APG-2449 in Patients With Advanced Solid Tumors
Ascentage Pharma Group Inc.
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
TOASTIT
Mayo Clinic
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
8479217
BerGenBio ASA
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Dendritic Cell Vaccination for Patients with Solid Tumors
University Hospital, Antwerp
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
PITHAC
Centre Hospitalier Universitaire Vaudois
REFIT-MSS
Translational Research in Oncology
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
A Study of SGN-CD228A in Advanced Solid Tumors
Seagen Inc.
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
REGOMUNE
Institut Bergonié
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
ImmVira Pharma Co. Ltd
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
National Institutes of Health Clinical Center (CC)
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
Fox Chase Cancer Center
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
National Institutes of Health Clinical Center (CC)
HOPE
Wake Forest University Health Sciences
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
Chinese PLA General Hospital
Immunotoxin Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
National Cancer Institute (NCI)
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Alanosine in Treating Patients With Cancer
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Cancer in the Abdomen
M.D. Anderson Cancer Center
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
National Cancer Institute (NCI)